Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast CancerHeikki Joensuu, Henrik Lindman, Päivi Auvinen et al.|JAMA Oncology|2018Cited by 149
Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for <i>ERBB2</i>-Positive Breast CancerHeikki Joensuu, Henrik Lindman, Judith Fraser et al.|JAMA Network Open|2024Cited by 2